Twist Bioscience (TWST) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.56
- Estimate
- -$0.18
- Surprise
- -212.4%
- Revenue (period 2026-06-30)
- $118.4M
- Score today
- 4.6/10
Revenue source: xbrl.
How the report landed
Twist Bioscience (TWST) reported a wider loss than forecast — diluted EPS of -$0.56 against the -$0.18 estimate (a 212.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates TWST Sell at 4.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -212.4% surprise compares with a -52.8% four-quarter average. Next scheduled report: 2026-11-16.
What argues against it
- Concentration risk — Product: synthetic DNA products
- Concentration risk — Supplier: single-source supplier
- Target reached (-37.1% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $144.00
- Price target
- $167.43
- Stop
- $135.40
- Upside to target
- +16.3%
Risk check: RSI 71 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-22 — shown for context, not personalized investment advice.
TWST at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $8.55B
- P/E (fwd)
- -215.3
- 52-week range
- $23.30–$145.51
- Off 52-week high
- 1.0%
- RSI (14)
- 71
- Volume vs avg
- 1.01×
- Score today
- 4.6/10